Colombian Registry of Anticoagulation Clinics and the Use of Reversal Agents

Anticoagulation has become a critically important therapeutic strategy for the prevention and management of conditions marked by hypercoagulability, which can lead to thrombosis or venous stasis with consequent clot formation and downstream complications.
Today, anticoagulation is indicated for patients with venous thromboembolism (VTE), atrial fibrillation (AF), hypercoagulable states such as thrombophilias, and cardiac valve prostheses—particularly mechanical valves. For many years, the principal agents have been heparin and vitamin K antagonists. In recent years, however, the introduction of direct oral anticoagulants (DOACs) has offered a safe alternative for VTE prophylaxis and treatment, as well as for reducing thromboembolic risk in non-valvular atrial fibrillation (NVAF). These newer agents demonstrate efficacy no less than warfarin and feature an improved bleeding-safety profile. Their limited availability of reversal agents and high market cost remain the main barriers to their broader use in our setting.

To implement a national registry of patients receiving anticoagulant therapy across multiple institutions in Colombia and analyze its association with potential factors linked to various outcomes.

It is expected that implementing the national registry of anticoagulated patients and those treated with reversal agents (RECCANT/RECCANT-AR) across different clinical settings will enhance our understanding of national epidemiology and provide a detailed sociodemographic and clinical characterization of this population.